In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Exelixis Inc (NASDAQ: EXEL) closed at $37.41 in the last session%, Down $-0.82% from day before closing price of $37.72. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 2.12 million shares were traded. EXEL stock price reached its highest trading level at $38.12 during the session, while it also had its lowest trading level at $37.265.
Ratios:
We take a closer look at EXEL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.36. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.51. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on July 08, 2025, Downgraded its rating to Sector Perform and sets its target price to $50 from $45 previously.
On June 24, 2025, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $60.
Wells Fargo Downgraded its Overweight to Equal Weight on February 24, 2025, while the target price for the stock was maintained at $36.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Eckhardt Sue Gail sold 18,838 shares for $42.74 per share. The transaction valued at 805,140 led to the insider holds 21,380 shares of the business.
WYSZOMIERSKI JACK L sold 7,535 shares of EXEL for $324,683 on Jun 03 ’25. The Director now owns 358,882 shares after completing the transaction at $43.09 per share. On Jun 03 ’25, another insider, JACK L WYSZOMIERSKI, who serves as the Director of the company, bought 7,535 shares for $43.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXEL now has a Market Capitalization of 10070884352 and an Enterprise Value of 9459610624. As of this moment, Exelixis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.94, and their Forward P/E ratio for the next fiscal year is 11.62. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.52 while its Price-to-Book (P/B) ratio in mrq is 4.97. Its current Enterprise Value per Revenue stands at 4.242 whereas that against EBITDA is 12.104.
Stock Price History:
The Beta on a monthly basis for EXEL is 0.32, which has changed by 0.40112364 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, EXEL has reached a high of $49.62, while it has fallen to a 52-week low of $25.12. The 50-Day Moving Average of the stock is -11.54%, while the 200-Day Moving Average is calculated to be -0.34%.
Shares Statistics:
According to the various share statistics, EXEL traded on average about 3.74M shares per day over the past 3-months and 4916550 shares per day over the past 10 days. A total of 270.13M shares are outstanding, with a floating share count of 260.58M. Insiders hold about 3.20% of the company’s shares, while institutions hold 93.43% stake in the company. Shares short for EXEL as of 1752537600 were 18267722 with a Short Ratio of 4.89, compared to 1749772800 on 20385497. Therefore, it implies a Short% of Shares Outstanding of 18267722 and a Short% of Float of 9.3100004.
Earnings Estimates
The current rating of Exelixis Inc (EXEL) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.65, with high estimates of $0.7 and low estimates of $0.6.
Analysts are recommending an EPS of between $2.79 and $2.64 for the fiscal current year, implying an average EPS of $2.71. EPS for the following year is $3.21, with 11.0 analysts recommending between $4.05 and $2.67.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $590.43M. It ranges from a high estimate of $633M to a low estimate of $571.52M. As of the current estimate, Exelixis Inc’s year-ago sales were $539.54MFor the next quarter, 17 analysts are estimating revenue of $608.85M. There is a high estimate of $649M for the next quarter, whereas the lowest estimate is $523.84M.
A total of 19 analysts have provided revenue estimates for EXEL’s current fiscal year. The highest revenue estimate was $2.4B, while the lowest revenue estimate was $2.22B, resulting in an average revenue estimate of $2.32B. In the same quarter a year ago, actual revenue was $2.17BBased on 19 analysts’ estimates, the company’s revenue will be $2.63B in the next fiscal year. The high estimate is $2.97B and the low estimate is $2.33B.
